Everything below concerns PPAR delta. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
=== Personal life === Humphreys married Nancy Wallace, a woman from a prominent Tulsa family, in 1960. The couple had two children, Claire and David. In 1974, Humphreys came out as a gay man during a discussion at a conference session at the ASA. Humphreys was a co-founder of the Sociologists' Gay Caucus (now the Committee on the Status of Lesbian, Gay, Bisexual, Transgender, and Queer People in Sociology), established in 1974 as a response to a presentation by Edward Sagarin that criticized homosexual sociologists as hiding in the closet. Humphreys separated from his wife in 1980 and began living with Brian Miller, a graduate student at the University of Alberta. With Miller, he co-authored articles about gay subcultures and victims of violent homophobia. Humphreys died of lung cancer on August 23, 1988, aged 57.
Cross-flowing is a passive formation method that involves the continuous and aqueous phases running at an angle to each other. Most commonly, the channels are perpendicular in a T-shaped junction with the dispersed phase intersecting the continuous phase; other configurations such as a Y-junction are also possible. The dispersed phase extends into the continuous and is stretched until shear forces break off a droplet. In a T-junction, droplet size and formation rate are determined by the flow rate ratio and capillary number. The capillary number relates the viscosity of the continuous phase, the superficial velocity of the continuous phase, and the interfacial tension. Typically, the dispersed phase flow rate is slower than the continuous flow rate. T-junction formation can be further applied by adding additional channels, creating two T-junctions at one location. By adding channels, different dispersed phases can be added at the same point to create alternating droplets of different compositions. Droplet size, usually above 10 μm, is limited by the channel dimensions and often produces droplets with a CV of less than 2% with a rate of up to 7 kHz.
=== Chemistry === Capensinidin (Cp), a blue-red plant dye Carbon monophosphide, a diatomic radical chemical compound Cassiopium (Cp), a name formerly used for the chemical element Lutetium Chlorinated paraffins (CPs), complex mixtures of polychlorinated n-alkanes Copernicium, a chemical element, with proposed symbol Cp Counterpoise method, a way to correct for basis set superposition error in quantum chemistry Cross-polarization Cyclopentadienyl complex (Cp), read as "C P", the cyclic C5H5 fragment in a coordination complex The similar symbol Cp* ("C P star") represents pentamethylcyclopentadienyl, the C5Me5 ligand
==== Netherlands ==== A brand called UGGO is sold in the Netherlands, which offers several different flavors of cream soda. The Surinamese soft drink brand Fernandes, widely available in the country, sells cream soda under the name Green Punch; as the name implies, it is green in color. Asian (especially Chinese) supermarkets also sell Schweppes Cream Soda, which is imported from Hong Kong. A&W is sold in some supermarkets. Old Jamaica Cream Soda (Jamaica) is also sold in the Netherlands.
Sources: en.wikipedia.org
set up a laboratory in the kitchen and woodshed of an old house in Washington near the area now occupied by buildings of the Department of Agriculture and there completed their researches on butter. This was the first dairy products research laboratory in Washington. Lore Rogers completed his first publications on butter. About this time he was elected to the Society of American Bacteriologists and in Washington married Beatrice Oberly, who was employed as bureau librarian. "Fishy Flavor in Butter" and "The Influence of Acidity of Cream on the Flavor of Butter" were published next. In 1909 the Dairy Research Laboratories were finally created and placed under the direction of Lore Rogers. His son, John Oberly Rogers, was born the same year. In 1911 he was selected as an official delegate representing the United States at the International Dairy Congress meeting at Stockholm. A publication on the spoiling of butter was published by the United States Department of Agriculture. By 1914 he was developing a procedure for preserving bacterial cultures by removing gas while in their frozen state. A few years later the United States Army would adopt the technique in the preparation of typhoid vaccines during World War I. In 1916 Lore Rogers became an advisory editor of the Journal of Bacteriology. A year later he was secretary of the Washington Branch of the Society of American Bacteriologists. In 1920 and 1921 he published articles on the manufacture of sweetened condensed milk and evaporated milk. In 1920 and 1922 he served as president of the American Society of Bacteriologists.
Mounting techniques were developed by Rudolf Heidenhain (1824–1898), who introduced gum Arabic; Salomon Stricker (1834–1898), who advocated a mixture of wax and oil; and Andrew Pritchard (1804–1884) who, in 1832, used a gum/isinglass mixture. In the same year, Canada balsam appeared on the scene, and in 1869 Edwin Klebs (1834–1913) reported that he had for some years embedded his specimens in paraffin. The 1906 Nobel Prize in Physiology or Medicine was awarded to histologists Camillo Golgi and Santiago Ramon y Cajal. They had conflicting interpretations of the neural structure of the brain based on differing interpretations of the same images. Ramón y Cajal won the prize for his correct theory, and Golgi for the silver-staining technique that he invented to make it possible.
=== Mechanism === The sulfhydryl groups of several cysteines surround the glucose binding site. All except cys 230 are essential for the catalytic process, forming multiple disulfide bridges during interaction with the substrates and regulators. At least in the beta cells, the ratio of active to inactive glucokinase molecules is at least partly determined by the balance of oxidation of sulfhydryl groups or reduction of disulfide bridges. These sulfhydryl groups are quite sensitive to the oxidation status of the cells, making glucokinase one of the components most vulnerable to oxidative stress, especially in the beta cells.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.